Intramuscular gene transfer of soluble B7.1/IgG(1) fusion cDNA induces potent antitumor immunity as an adjuvant for DNA vaccination.
Soluble B7.1/IgG Fc fusion protein, which has costimulatory effects, is an effective molecular adjuvant in tumor immune therapy. Here, we describe a nonviral intramuscular (i.m.) gene transfer method to deliver this therapeutic protein. Gene transfer was greatly enhanced by electroporation and highly efficient production of this protein was achieved. Serum levels reached up to 1 microg/ml with considerable length of expression and without apparent systemic adverse effects. Lymphocytes from mice coinjected with soluble B7.1/IgG(1) and carcinoembryonic antigen (CEA)-encoding plasmids showed significantly elevated CEA-stimulated proliferation, cytokine production, and cytotoxic T-lymphocyte (CTL) activity. These mice gained significant protection against a CEA-positive transplanted tumor, in terms of reduced tumor incidence and growth. The effects were superior when soluble B7.1/IgG(1) was expressed as compared to membrane-bound wild-type B7.1. Notably, expression of soluble B7.1/IgG(1) alone did not induce any protection against tumor, confirming its primary role as a costimulatory molecule rather than a direct antitumor agent. The plasmid encoding B7.1/IgG(1) did not have to be injected at the same site as the antigen-encoding plasmid to exert its adjuvant effect, indicating that circulating protein was sufficient. Muscle histopathology revealed minimal damage to DNA-injected muscles. Importantly, we show that, after gene transfer, muscle tissue can produce this protein in large quantity to exert its immune costimulatory effect for cancer therapy and it would be otherwise difficult and expensive to maintain this high a level of recombinant protein.
Zhou
Zheng F
ZF
Department of Pathology, McGill University, Montréal, Québec, Canada H3A 2B4.
Peretz
Yoav
Y
Chang
Yigang
Y
Miao
Deng Shun
DS
Li
Xiaoying
X
Prud'homme
Gérald J
GJ
D000818:Animals; D018122:B7-1 Antigen / Q000235:genetics*; D018827:Carcinoma, Lewis Lung; D002455:Cell Division; D004247:DNA / Q000378:metabolism; D018076:DNA, Complementary / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D007074:Immunoglobulin G / Q000235:genetics* / Q000378:metabolism; D007150:Immunohistochemistry; D008214:Lymphocytes / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D009369:Neoplasms / Q000517:prevention & control*; D010455:Peptides / Q000737:chemistry; D010957:Plasmids / Q000378:metabolism; D013997:Time Factors; D014162:Transfection; D019444:Vaccines, DNA
D018122:B7-1 Antigen; D018076:DNA, Complementary; D007074:Immunoglobulin G; D010455:Peptides; D019444:Vaccines, DNA; D004247:DNA